<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03841604</url>
  </required_header>
  <id_info>
    <org_study_id>Z7219M01</org_study_id>
    <nct_id>NCT03841604</nct_id>
  </id_info>
  <brief_title>Effect of Safinamide on Parkinson's Disease Related Chronic Pain</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Safinamide 100mg Once Daily, as add-on Therapy, in Idiopathic Parkinson's Disease (PD) Patients With Motor Fluctuations and PD Related Chronic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zambon SpA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zambon SpA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase IV, international, multicentre, randomised, double-blind, placebo controlled&#xD;
      study in IPD patients, experiencing motor fluctuations and PD related chronic pain while on&#xD;
      stable doses of levodopa (L-Dopa).&#xD;
&#xD;
      Participants will be randomized 2:1 to receive either active or placebo&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an international, multicentre, randomised, double-blind, placebo-controlled study.&#xD;
&#xD;
      Patients will be randomized 2:1 to receive either active and placebo Approximately 132&#xD;
      participants will be screened, of which 105 will be enrolled Study participation will be up&#xD;
      to a maximum duration of 19 weeks and will comprise a screening period (1 to 2 weeks) and a&#xD;
      treatment period (16 weeks). A telephone follow-up call will be performed 1 week after the&#xD;
      end of treatment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 9, 2019</start_date>
  <completion_date type="Actual">May 3, 2021</completion_date>
  <primary_completion_date type="Actual">April 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the potential efficacy of safinamide 100 mg od, compared to placebo, as add-on therapy, for PD related chronic pain: Numerical Rating Scale (NRS)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in pain severity (&quot;average worst pain experienced in the last 7 days&quot;), as assessed by an 11-point Numerical Rating Scale (NRS).&#xD;
[0 point is the minimum and 10 point is the maximum. The higher the score, the more severe the pain]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of pain responders</measure>
    <time_frame>16 weeks</time_frame>
    <description>Reduction in pain severity of ≥2 points (&quot;average worst pain experienced in the last 7 days&quot;) as assessed by an 11-point NRS, compared to baseline [0 point is the minimum and 10 point is the maximum. The higher the score, the more severe the pain]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression for pain (change)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in the CGI-C (Clinical Global Impression - Change) score for pain [ a seven-point scale, it ranges from Very much Improved to Very much Worse]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression for pain (severity)</measure>
    <time_frame>16 weeks</time_frame>
    <description>The CGI-S (Clinical Global Impression - Severity) score for pain at week 16 [ a seven-point scale, it ranges from Very much Better to Very much Worse]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression for pain</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in the PGI-C (Patient Global Impression - Change) score for pain&#xD;
[ a seven-point scale, it ranges from Very much Better to Very much Worse]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of pain drugs (Percentage)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Percentage of reduction in number of concomitant pain drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of pain drugs (amount)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Amount of PRN pain medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of pain drugs</measure>
    <time_frame>16 weeks</time_frame>
    <description>Number of patients with at least one intake of PRN pain medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in the Hospital Anxiety and Depression Scale (HADS) score&#xD;
[Fourteen item scale, seven items relate to anxiety and seven relate to depression. The anxiety and depression subscales each range from 0 to 21, with higher scores indicating higher anxiety/depression complains]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor and non-motor symptoms</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in the MDS-UPDRS (total score and subscores)&#xD;
[The MDS-UPDRS has four parts: Part I (non-motor experiences of daily living), Part II (motor experiences of daily living, Part III (motor examination) and Part IV (motor complications)]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Idiopathic Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Safinamide methanesulfonate film coated tablets once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Safinamide methanesulfonate matching placebo film coated tablets once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Safinamide Methanesulfonate</intervention_name>
    <description>50 mg, 100 mg</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Safinamide methanesulfonate matching placebo</intervention_name>
    <description>50 mg, 100 mg</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant must be 30 years of age or older, at the time of signing the informed&#xD;
             consent.&#xD;
&#xD;
          2. Diagnosed with IPD by using the United Kingdom Parkinson's Disease Society Brain Bank&#xD;
             criteria for more than 5 years duration.&#xD;
&#xD;
          3. Receiving treatment with a stable dose of oral L-Dopa (including controlled release&#xD;
             [CR], immediate release [IR] or a combination of CR/IR), with and without&#xD;
             benserazide/carbidopa, with or without addition of a catechol O-methyltransferase&#xD;
             (COMT) inhibitor and may be receiving concomitant treatment with stable doses of a&#xD;
             dopamine agonist, an anticholinergic and/or amantadine for at least 4 weeks prior to&#xD;
             the randomisation (baseline visit).&#xD;
&#xD;
          4. Hoehn and Yahr stage between 2-3 (inclusive) during the &quot;ON&quot; phase at the screening&#xD;
             visit.&#xD;
&#xD;
          5. Experiencing motor fluctuations following optimum titration of treatment medications&#xD;
             and within the 4 weeks immediately prior to randomisation.&#xD;
&#xD;
          6. Experiencing chronic pain (i.e. ongoing for ≥3 months prior to screening visit); the&#xD;
             Investigator must consider chronic pain directly related to PD and not explained by&#xD;
             any other health problem (e.g. peripheral neuropathy, organ disease or arthritis pain)&#xD;
             OR consider the intensity of chronic pain specifically aggravated by PD.&#xD;
&#xD;
          7. If taking regular analgesics, the treatment regimen should be stable in the 4 weeks&#xD;
             prior to the randomisation visitt.&#xD;
&#xD;
          8. Able to maintain an accurate and complete electronic diary with the help of a&#xD;
             caregiver.&#xD;
&#xD;
          9. Male or female&#xD;
&#xD;
             •A female participant is eligible to participate if she is not pregnant, not&#xD;
             breastfeeding, and at least one of the following conditions applies: i.Not a woman of&#xD;
             childbearing potential (WOCBP) OR ii.A WOCBP who agrees to follow the contraceptive&#xD;
             guidance&#xD;
&#xD;
         10. Capable of giving signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any form of Parkinsonism other than IPD.&#xD;
&#xD;
          2. Diagnosis of chronic migraine (&gt;15 days per month) or cancer pain.&#xD;
&#xD;
          3. History of bipolar disorder, depression, schizophrenia or other psychotic disorder&#xD;
             requiring treatment with neuroleptics.&#xD;
&#xD;
          4. History of dementia or cognitive dysfunction.&#xD;
&#xD;
          5. Severe, peak dose or biphasic dyskinesia.&#xD;
&#xD;
          6. Unpredictable or widely swinging fluctuations.&#xD;
&#xD;
          7. Ophthalmologic history including any of the following conditions: albinism, uveitis,&#xD;
             retinitis pigmentosa, retinal degeneration, active retinopathy, severe progressive&#xD;
             diabetic retinopathy, inherited retinopathy or family history of hereditary retinal&#xD;
             disease.&#xD;
&#xD;
          8. Moderate or severe liver failure using the Child-Pugh classification score.&#xD;
&#xD;
          9. History of drug and/or alcohol abuse within 12 months prior to screening as defined by&#xD;
             the current edition of the Diagnostic and Statistical Manual of Mental Disorders.&#xD;
&#xD;
         10. Allergy/sensitivity, intolerance or contraindications to Safinamide.&#xD;
&#xD;
         11. Treatment with monoamine oxidase inhibitors (MAOIs), levodopa infusion, pethidine,&#xD;
             fluoxetine, fluvoxamine less than 4 weeks prior to the randomisation visit&#xD;
&#xD;
         12. Use of any investigational drug or device within 30 days prior to screening or 5&#xD;
             half-lives, whichever is the longest&#xD;
&#xD;
         13. Previous treatment with Safinamide in the 9 months before the screening visit&#xD;
&#xD;
         14. Mini-Mental State Exam (MMSE) total score &lt;24 at screening.&#xD;
&#xD;
         15. NRS score ≤ 4 points at randomization visit.&#xD;
&#xD;
         16. Any clinically significant condition which, in the opinion of the Investigator, would&#xD;
             not be compatible with study participation or represent a risk for participants while&#xD;
             in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medizinische Universitat Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut für Neuroimmunologische und Neurodegenerative Erkrankungen</name>
      <address>
        <city>Wien</city>
        <zip>1220</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de GRENOBLE</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux de La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30900</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pierre-Paul Riquet</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Krankenhaus Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13088</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus an der TU Dresden</name>
      <address>
        <city>Dresde</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katholische Kliniken Ruhrhalbinsel GmbH</name>
      <address>
        <city>Essen</city>
        <zip>45257</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Praxis</name>
      <address>
        <city>Gera</city>
        <zip>07551</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medicine Göttingen Germany</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Haag i. OB</name>
      <address>
        <city>Haag</city>
        <zip>83527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg GmbH</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroPoint Akademie</name>
      <address>
        <city>Ulm</city>
        <zip>89073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Chieti</city>
        <zip>66013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro per la Malattia di Parkinson e i Disturbi del Movimento</name>
      <address>
        <city>Milano</city>
        <zip>20126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele S.r.l. - PPDS</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Di Perugia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Neurologico Mediterraneo Neuromed</name>
      <address>
        <city>Pozzilli</city>
        <zip>86077</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione PTV Policlinico Tor Vergata</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni Battista - ACISMOM</name>
      <address>
        <city>Roma</city>
        <zip>00148</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS San Raffaele Pisana</name>
      <address>
        <city>Roma</city>
        <zip>00163</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria OO.RR. San Giovanni di Dio Ruggi d'Aragona</name>
      <address>
        <city>Salerno</city>
        <zip>84084</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de La Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebrón - PPDS</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.A.U de Burgos - Hospital Universitario de Burgos</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta del Mar</name>
      <address>
        <city>Cadiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Donostia</name>
      <address>
        <city>Donostia</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz - PPDS</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro - Majadahonda</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital HM Puerta del Sur</name>
      <address>
        <city>Móstoles</city>
        <zip>28938</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 30, 2019</study_first_submitted>
  <study_first_submitted_qc>February 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

